Splenocytes from mice immunized with homogenous, polyclonal, rabbit kinin antibody (BK21) were fused using polyethylene glycol with the mouse myeloma cell line SP2/o. Eleven monoclonal antibodies, whose binding to BK21 could be inhibited by bradykinin, were obtained from 3 fusions. All of these anti-idiotypic antibodies were of the IgG1k isotype, except for one, which was an IgG2ak. An IgMk, auto-anti-idiotypic antibody, reactive with BK21 was obtained from a fusion of SP2/o cells and splenocytes from a mouse immunized with bradykinin conjugated with carbodiimide to keyhole limpet hemocyanin. Bradykinin could completely inhibit the binding of all of the anti-idiotypic antibodies to BK21 in an enzyme-linked immunosorbent assay. This result is consistent with the anti-idiotypic antibodies being reactive with the ligand binding sites of BK21. It was possible to separate the anti-idiotypic antibodies into 2 groups. The first group, 10 of the 12 antibodies tested, was more sensitive to inhibition by bradykinin than the second group and was not readily inhibited by des-Arg9-bradykinin. The second group was about 7 times more sensitive to inhibition by des-Arg9-bradykinin than by bradykinin. Further experiments will be needed to determine whether or not these monoclonal anti-idiotypic antibodies are "internal image" antibodies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/hyb.1993.12.45 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database.
Sci Rep
March 2025
Department of Pediatrics, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, 130021, Jilin, China.
Omalizumab is a biologic agent used in the management of allergic conditions, including asthma and urticaria. Although the efficacy of omalizumab has been well established, its safety profile is primarily derived from clinical trials with limited sample sizes. To conduct a comprehensive evaluation of its safety in larger populations, this study conducted an extensive analysis of data sourced from the America Food and Drug Administration's Adverse Event Reporting System (FAERS), with the aim of elucidating adverse drug events associated with omalizumab in real-world settings.
View Article and Find Full Text PDFEffectiveness of biological therapy in severe asthma: a retrospective real-world study.
Croat Med J
February 2025
Marina Lampalo, Clinical Department for Lung Diseases Jordanovac, University Hospital Center Zagreb, Jordanovac 104, 10000 Zagreb, Croatia,
Unlabelled: Aim- To compare the effectiveness of different biologic medications for the treatment of severe asthma.
Methods: We retrospectively collected data on 74 patients treated with one of four different biologics (omalizumab, mepolizumab, reslizumab, or benralizumab) at the Jordanovac Clinic for Pulmonary Diseases, Zagreb, Croatia for at least two years. The patients were compared in terms of the number of exacerbations, dose of oral corticosteroids (OCS), asthma control test (ACT), forced expiratory volume in 1 second (FEV1), forced vital capacity, fraction of exhaled nitric oxide (FeNO), number of blood eosinophils, and total immunoglobulin E (IgE).
Frequency of IgE antibody response to SARS-CoV-2 RBD protein across different disease severity COVID19 groups.
Virol J
March 2025
Rheumatology Service, Departament de Medicina, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Sabadell, Spain.
Background: COVID-19 appears to have a progression of three stages. The latter stage is characterized by a high level of cytokine release, which in turn triggers an uncontrolled reaction known as cytokine storm where mast cells are involved. The presence of anti-IgE antibodies against SARS-CoV-2 in this phase has been previously reported, suggesting an association with the severity of the disease.
View Article and Find Full Text PDFPharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe.
Immunotherapy
February 2025
Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA.
Aims: To demonstrate pharmacokinetic equivalence of CT‑P39 administered via auto-injector (CT‑P39 AI) and European Union-approved reference omalizumab via pre-filled syringe (EU-OMA PFS) in healthy Japanese adults.
Participants & Methods: This open-label, Phase 1 study randomized participants (1:1) to a single 150 mg/mL dose of CT‑P39 AI or EU-OMA PFS. The primary endpoint was pharmacokinetic equivalence per area under the concentration-time curve from time zero to infinity (AUC) and maximum serum concentration (C).
The data on subphenotypes and treatment responses to biologicals in late-onset asthma (LOA) is limited. This study aims to compare the clinical characteristics and treatment responses in severe asthma patients receiving biological treatments, categorized into early-onset asthma (EOA) and LOA groups. Patients treated with omalizumab or mepolizumab for at least six months at a tertiary care adult allergy clinic between December 2015 and December 2023 were included.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!